JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

JNJ

170.73

-0.23%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

TMO

466.56

-0.22%↓

ISRG

476.87

-1.3%↓

Search

Eli Lilly and Co.

Suletud

SektorTervishoid

765.52 -0.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

759.46

Max

769.31

Põhinäitajad

By Trading Economics

Sissetulek

-6.1B

2.8B

Müük

-804M

13B

P/E

Sektori keskmine

66.239

40.048

Dividenditootlus

0.66

Kasumimarginaal

21.678

Töötajad

47,000

EBITDA

-2B

4.2B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+34.95% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.66%

2.45%

Järgmine tulemuste avaldamine

7. aug 2025

Järgmine dividendimakse kuupäev

10. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

15. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-98B

730B

Eelmine avamishind

765.78

Eelmine sulgemishind

765.52

Uudiste sentiment

By Acuity

60%

40%

331 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Eli Lilly and Co. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuni 2025, 11:56 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

27. mai 2025, 14:41 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

30. juuli 2025, 10:38 UTC

Market Talk

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29. juuli 2025, 17:05 UTC

Tulu

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29. juuli 2025, 16:55 UTC

Tulu

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29. juuli 2025, 13:35 UTC

Tulu

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29. juuli 2025, 11:39 UTC

Tulu

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25. juuli 2025, 12:49 UTC

Omandamised, ülevõtmised, äriostud

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

24. juuli 2025, 12:02 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV

24. juuli 2025, 12:01 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: About 55.7% of Verve Shares Tendered >LLY VERV

24. juuli 2025, 12:00 UTC

Omandamised, ülevõtmised, äriostud

Lilly and Verve Announce Expiration of Verve Tender Offer

9. juuli 2025, 09:17 UTC

Kuumad aktsiad

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

17. juuni 2025, 14:02 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17. juuni 2025, 12:12 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17. juuni 2025, 11:01 UTC

Omandamised, ülevõtmised, äriostud

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17. juuni 2025, 10:47 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17. juuni 2025, 10:47 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17. juuni 2025, 10:46 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17. juuni 2025, 10:45 UTC

Omandamised, ülevõtmised, äriostud

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17. juuni 2025, 09:33 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

11. juuni 2025, 09:45 UTC

Market Talk

Next Generation Obesity Drugs in Focus at American Diabetes Association Event -- Market Talk

29. mai 2025, 01:00 UTC

Peamised uudised

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28. mai 2025, 18:09 UTC

Tulu

Heart Disease Could Be a Goner When These New -2-

28. mai 2025, 18:09 UTC

Tulu

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27. mai 2025, 14:02 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27. mai 2025, 14:01 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27. mai 2025, 14:00 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27. mai 2025, 14:00 UTC

Omandamised, ülevõtmised, äriostud

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20. mai 2025, 14:08 UTC

Tulu

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12. mai 2025, 22:14 UTC

Peamised uudised

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

Võrdlus sarnastega

Hinnamuutus

Eli Lilly and Co. Prognoos

Hinnasiht

By TipRanks

34.95% tõus

12 kuu keskmine prognoos

Keskmine 1,028.8 USD  34.95%

Kõrge 1,190 USD

Madal 883 USD

Põhineb 19 Wall Streeti analüütiku instrumendi Eli Lilly and Co. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

19 ratings

17

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 884.54Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

331 / 374 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.